Wilex: Seeking Partners For Novel ADC Technology
Edison | Nov 06, 2015 01:29AM ET
Seeking partners for novel ADC technology
Wilex's (DE:WL6G) subsidiary, Heidelberg Pharma, is developing antibody-targeted amanitin conjugates (ATACs), which are differentiated from first-in-class, and developing antibody drug conjugates by potential efficacy against dormant and proliferating tumours. The investment case rests on the new partnerships for the ATAC pipeline and on clinical partnering progress for renal cancer programmes. Our DCF valuation is €41m.
The power of ATACs
Wilex’s ATACs use the toxin α-Amanitin from the green death cap mushroom. The principle of anti-cancer antibody drug conjugates (ADCs) is to use the very high specificity of antibodies and link them to toxic small molecules. ATACs could prevent tumour relapse and resistance in slower-growing tumours, while many ADC technologies block only proliferating tumour cells. Wilex has a proprietary preclinical pipeline of undisclosed ATACs. Separately, it is developing ATACs against prostate-specific membrane antigen (PSMA) in prostate tumours.
Seeking out new ventures
In August, Roche (OTC:RHHBY) communicated its strategic decision to discontinue its ATAC collaboration with Heidelberg Pharma. The decision was chiefly based on Roche’s immunotherapy focus, despite very good progress made in the ATAC collaboration. Wilex continues to seek new alliances for its proprietary pipeline based on its pioneering approach in ADC cancer therapy. Preclinical results published in Nature this year are likely to assist Wilex in its discussions with future licence partners. The clinical pipeline includes uPA inhibitor Mesupron out-licensed in oncology. Wilex seeks separate partners to progress its Phase III clear cell renal cancer products.
To Read the Entire Report Please Click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.